Cipher Pharmaceuticals Inc. (CPH) EPS Estimated At $0.10; TG Therapeutics (TGTX) Shorts Decreased By 1.65%

Analysts expect Cipher Pharmaceuticals Inc. (TSE:CPH) to report $0.10 EPS on February, 27.They anticipate $0.09 EPS change or 47.37% from last quarter’s $0.19 EPS. T_CPH’s profit would be $2.68 million giving it 4.78 P/E if the $0.10 EPS is correct. After having $0.04 EPS previously, Cipher Pharmaceuticals Inc.’s analysts see 150.00% EPS growth. The stock increased 1.60% or $0.03 during the last trading session, reaching $1.91. About 4,165 shares traded. Cipher Pharmaceuticals Inc. (TSE:CPH) has 0.00% since February 13, 2018 and is . It has by 0.00% the S&P500.

TG Therapeutics Inc (NASDAQ:TGTX) had a decrease of 1.65% in short interest. TGTX’s SI was 10.83M shares in February as released by FINRA. Its down 1.65% from 11.01 million shares previously. With 1.37M avg volume, 8 days are for TG Therapeutics Inc (NASDAQ:TGTX)’s short sellers to cover TGTX’s short positions. The SI to TG Therapeutics Inc’s float is 20.19%. The stock decreased 0.88% or $0.04 during the last trading session, reaching $4.49. About 525,701 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has declined 37.94% since February 13, 2018 and is downtrending. It has underperformed by 37.94% the S&P500. Some Historical TGTX News: 06/03/2018 TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2017 Financial Results and Business Update; 08/05/2018 – TG THERAPEUTICS INC – CASH, CASH EQUIVALENTS, INVESTMENT SECURITIES, AND INTEREST RECEIVABLE WERE $109.2 MILLION AS OF MARCH 31, 2018; 15/05/2018 – Ra Capital Management Buys New 3.2% Position in TG Therapeutics; 08/03/2018 – TG Therapeutics 4Q Loss $30.9M; 17/05/2018 – TG Therapeutics, Inc. Announces Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Onco; 21/05/2018 – TG Therapeutics Presenting at Conference Jun 4; 07/04/2018 – TG Therapeutics Access Event Scheduled By B. Riley FBR, Inc; 24/04/2018 – TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the American Academy of Neurology 70th Annual Meeting; 04/05/2018 – TG Therapeutics, Inc. to Host Conference Call on First Quarter 2018 Financial Results and Business Update; 19/04/2018 – TG Therapeutics Closes Above 50-Day Moving Average: Technicals

Cipher Pharmaceuticals Inc., together with its subsidiaries, operates as a specialty pharmaceutical dermatology firm in South America, Canada, and the United States. The company has market cap of $51.23 million. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. It has a 9.5 P/E ratio. The firm also provides BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; and Sitavig, a tablet for the treatment of herpes labialis in immunocompetent adults.

Investors sentiment decreased to 1.1 in Q3 2018. Its down 0.37, from 1.47 in 2018Q2. It is negative, as 23 investors sold TG Therapeutics, Inc. shares while 27 reduced holdings. 22 funds opened positions while 33 raised stakes. 45.96 million shares or 15.90% more from 39.66 million shares in 2018Q2 were reported. Citigroup Inc holds 170,995 shares. Willingdon Wealth Mngmt has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 4 shares. Group Inc Incorporated One Trading Limited Partnership owns 0.01% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 145,645 shares. 500,000 were accumulated by 683 Mngmt Limited Co. California-based Parallax Volatility Advisers Lp has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). 4.14M were accumulated by State Street Corporation. Hikari Power Limited has invested 0.09% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). Blackrock owns 4.42 million shares. Macquarie Group Inc Ltd has 500 shares. Artal Gru holds 0.06% in TG Therapeutics, Inc. (NASDAQ:TGTX) or 400,000 shares. Credit Agricole S A holds 1.32 million shares or 0.35% of its portfolio. Boothbay Fund Ltd Co, New York-based fund reported 39,865 shares. Balyasny Asset Ltd Liability Company holds 0% or 102,571 shares. Savings Bank Of Mellon has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 286,843 shares. Raymond James Serv Advsr stated it has 145,595 shares.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $344.95 million. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-HodgkinÂ’s lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

More notable recent TG Therapeutics, Inc. (NASDAQ:TGTX) news were published by: which released: “Has TG Therapeutics (TGTX) Outpaced Other Medical Stocks This Year? – Nasdaq” on January 28, 2019, also with their article: “TG Therapeutics (TGTX) Upgraded to Buy: Here’s What You Should Know – Nasdaq” published on January 30, 2019, published: “Health Care Sector Update for 01/22/2019: TGTX, SRNE, JNJ, ABT, MRK, AMGN, PFE – Nasdaq” on January 22, 2019. More interesting news about TG Therapeutics, Inc. (NASDAQ:TGTX) were released by: and their article: “Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings? – Nasdaq” published on February 11, 2019 as well as‘s news article titled: “APHA, EBAY among premarket gainers – Seeking Alpha” with publication date: January 22, 2019.

TG Therapeutics, Inc. (NASDAQ:TGTX) Institutional Positions Chart